Williams Cancer Institute Unveils Groundbreaking Data on Combined Treatment for Head and Neck Cancer
The Williams Cancer Institute (WCI) has recently unveiled groundbreaking research at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, presenting a novel approach to treating head and neck squamous cell carcinoma (HNSCC). This study, led by Dr. Jason Williams, highlights the potential of combining pulsed electrical field ablation with intratumoral immunotherapy, offering new hope for patients with advanced HNSCC.
A Revolutionary Approach to Cancer Treatment
Dr. Williams and his team focused on a patient with advanced HNSCC, a cancer often caused by tobacco use or HPV infection and challenging to treat with conventional methods. The innovative treatment involved a combination of two cutting-edge techniques:
- Pulsed Electrical Field Ablation: A minimally invasive procedure that uses electrical pulses to disrupt tumor cells, making them more susceptible to the body's immune system.
- Intratumoral Immunotherapy: A targeted approach where immunotherapy is directly injected into the tumor, stimulating the body's immune response to fight the cancer.
The treatment regimen was carefully designed to maximize its effectiveness:
- Four Cycles of Ablation: During the initial session, four cycles of pulsed electrical field ablation were administered to disrupt the tumor cells.
- Intratumoral Immunotherapy Injections: A unique combination of immunotherapy, iodinated contrast for imaging, and gelfoam slurry for local retention was injected directly into the tumor.
- Ongoing Immunotherapy: Additional immunotherapy injections were administered at weeks three and four, and again at eight months post-treatment, ensuring a sustained immune response.
Impressive Results and Safety Profile
The results of this study are remarkable. The patient experienced substantial tumor regression and a durable clinical response, with no treatment-related toxicity or procedural complications. At 14 months, imaging revealed complete radiologic and immunologic tumor elimination, and by 22 months, the patient's disfiguring mass had fully resolved.
A New Hope for Patients
Dr. Williams emphasizes the potential of this combined approach to offer new hope for patients with difficult-to-treat tumors who are not candidates for conventional therapies. The study's findings reinforce the importance of precision-based local ablation and intratumoral immunotherapy in activating an immune response against cancer.
Further Exploration and Future Directions
The full article, titled '702 Pulsed electrical field ablation plus intratumoral immunotherapy for head and neck squamous cell carcinoma,' is available in the Journal for ImmunoTherapy of Cancer. Williams Cancer Institute continues to lead the way in advancing safer, less invasive, and more effective treatment options, bringing new hope to patients facing challenging cancers.
